<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To retrospectively study the prophylaxis of invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> in neutropenic patients and to relate the frequency of this <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal disease</z:e> to any causal or modifying factors that could be identified </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Between 1977 and 1988, 130 patients underwent 158 intensive treatment episodes to control <z:hpo ids='HP_0002488'>acute leukemia</z:hpo>, <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, and the frequency of complicating <z:e sem="disease" ids="C0851807" disease_type="Disease or Syndrome" abbrv="">aspergillus infection</z:e> was determined </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Proven invasive <z:e sem="disease" ids="C0851807" disease_type="Disease or Syndrome" abbrv="">aspergillus infections</z:e> occurred in 22 cases, 12 of which were fatal </plain></SENT>
<SENT sid="3" pm="."><plain>Invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> was suspected in a further 16 cases and <z:hpo ids='HP_0000001'>all</z:hpo> these patients recovered with <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Colonization by Aspergillus in the absence of clinically significant <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was seen in 31 treatment episodes </plain></SENT>
<SENT sid="5" pm="."><plain>Invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> involved mainly the upper and lower respiratory tract and skin </plain></SENT>
<SENT sid="6" pm="."><plain>Control of the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was closely related to the control of the underlying disease, with subsequent return of <z:mpath ids='MPATH_458'>normal</z:mpath> marrow function and resolution of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence of <z:e sem="disease" ids="C0851807" disease_type="Disease or Syndrome" abbrv="">aspergillus infection</z:e> has decreased dramatically since 1985, most probably due to the introduction of intranasal <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>This occurred despite the persistence of aspergillus spores in the hematology ward air during the 1986 to 1988 period </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Intranasal aerosolized <z:chebi fb="1" ids="2682">amphotericin B</z:chebi> may protect against invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e>, even when neutropenic patients are cared for in conventional wards without HEPA filtration </plain></SENT>
</text></document>